Mr. Moch joined Cognition Therapeutics in October 2016 as president and chief executive officer. He has broad expertise building, financing and leading private and public life science companies from start-up through commercialization, having previously served as president and CEO of four life science companies: Chimerix, Inc., an antiviral therapeutics company; BioMedical Enterprises (acquired by DePuy, a Johnson & Johnson company), a manufacturer and marketer of nitinol orthopedic implants; Alteon, Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications; and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank.
Mr. Moch started his career in biotech drug development as a co-founder and vice president of The Liposome Company, Inc. (acquired by Elan Corporation), a pioneer in the use of liposomes for the delivery of anticancer and antifungal drugs. He has also been a managing partner of The Salutramed Group, LLC, a managing director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc.
Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. Using her 15 years of industry experience, she and her team discovered and developed the company’s drug candidate Elayta (CT1812), currently in clinical testing for the treatment of patients with mild-to-moderate Alzheimer’s disease.
Prior to founding Cognition Therapeutics, Dr. Catalano was director of discovery biology for Acumen Pharmaceuticals, leading the team that discovered Acumen’s lead candidates targeting Aβ oligomers. Earlier at Rigel, she led the team that pioneered the use of high content phenotypic screening to discover the Aurora kinase inhibitor R763. In scientific leadership roles within the neurophysiology and neuroimaging groups at Roche Palo Alto she led exploratory programs against targets involved in anxiety, depression and schizophrenia.
Dr. Catalano received her Ph.D. from U.C. Irvine and postdoctoral training at U.C. Berkeley with Dr. Carla Shatz and at Caltech with Drs. Mary Kennedy and Scott Fraser studying the neurobiology of synaptic plasticity.
Mr. Gailus is a former member of the New York Angels and has been the venture advisor to OgdenCAP Associates LLC in New York City since 2006. His expertise is identifying early stage investment opportunities and working with companies on their strategic direction and focus, adding or strengthening their management skills and organizational processes, recruiting outside board members and ensuring that they have adequate capital to execute their business plan.
In addition to his board role at Cognition Therapeutics, Inc. he serves as a director on the boards of Tetragenetics, Inc., WayWire, Inc., FASTTAC, Inc., and chairman of the board of GlobalPay, Inc. Mr. Gailus has a B.A. in American studies from Columbia College (Academic All-American) and an M.B.A. from the Columbia Graduate School of Business.
Mr. Breedlove is general partner for the Breedlove Family Limited Partnership, a family investment partnership and acts as managing partner with specific responsibility for its direct investments in private companies. Since 2006 the partnership has been an angel investor in early stage life sciences companies with five current active interests. Mr. Breedlove has responsibilities as a board member for Cognition Therapeutics and sits on the board of one other life sciences company and one manufacturing company.
Mr. Breedlove is also president and CEO of Keystone Profiles, Ltd. which he founded in 2004. Prior to founding Keystone Profiles, Mr. Breedlove served at Qualitor, Inc. as president and COO and board member. Before joining Qualitor, Mr. Breedlove enjoyed a 19-year career with Allied Signal, Inc., and served as corporate officer and member of AlliedSignal’s Corporate Executive Committee while leading Allied Signal’s Friction Materials business, a >$900 million global company with manufacturing plants, distribution centers and engineering labs on five continents.
Mr. Breedlove’s charitable activities include board membership for Laurel Highlands Council, Boy Scouts of America; Board President, Beaver County Educational Trust; Co-chair Dean’s Development Council, College of Education, The Pennsylvania State University.
Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years. Dr. Fletcher has a strong understanding of commercial viability in the marketplace through his activities as a healthcare consultant to provide fundamental healthcare intelligence focused on the biotech and med-tech sub-sectors.
Dr. Fletcher is the founder and president of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. He holds a Ph.D. in biochemistry from Colorado State University and serves as a professor at Dallas Baptist University where he teaches biochemistry, bioethics and cell biology.
Dr. Scher has held senior positions in drug development at Merck and Co., Astra Merck and Merck KGaA, where he led and supervised teams that developed drugs in many different fields of medicine. He is currently chairman and a founder of Opertech Bio., a Philadelphia-based company that quantitatively measures human taste. He is chairman of VaxImmune, a Houston, Texas-based company developing a novel method to culture and detect Streptococcal infections which will also serve as a platform for detecting other bacterial and viral infections. He was CEO of Biosynexus and lead a team that studied the ability of a monoclonal antibody to prevent Staphylococcal infections in premature infants. He is a founder and board member of Iron Batteries Incorporated, an early stage company developing a novel method of storing energy, based in Santa Rosa California. He served on the board of Intarcia Therapeutics from 2007 to 2017, a Boston-based company that has raised over $1 Billion and is preparing an NDA for a method to treat diabetes. He also served as a board member of Redpoint Biology and Clarient. He currently is involved as an investor and board member of a number startup companies.
Ms. Wallace joined the Cognition Therapeutics board in January 2017. She is a managing partner at Golden Seeds, a venture capital firm dedicated to raising capital for women entrepreneurs and to encouraging both women and men to become active venture investors. She is a general partner of Golden Seeds Fund and Golden Seeds Fund 2 and works with companies and their board representatives to build a post-investment environment that fosters the growth of companies in the portfolio.
Ms. Wallace has more than 25 years’ experience on Wall Street at JP Morgan, Salomon Brothers, and XL Capital, focusing on complex financial structures, credit, derivatives, mergers and acquisitions, and risk management. She holds a B.A. from The George Washington University.
Stephen Sands is the vice chairman of investment banking and chairman of the Global Healthcare Group at Lazard, a leading financial advisory and asset management firm. Mr. Sands has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally. Prior to joining Lazard, Mr. Sands was a partner in the healthcare practice of McKinsey & Company. During his career, he has co-founded two life sciences companies: Enzytech (acquired by Alkermes) and Opta Food Ingredients (acquired by Stake Technology). Mr. Sands has also served as director on the boards of several life sciences companies, including National Imaging Associates, Inc. (acquired by Magellan Health Services), and Isogen LLC (acquired by Monsanto).
Mr. Sands is a member of the Rockefeller University Council, the Washington University (St. Louis) School of Engineering & Applied Science National Counsel, the National Campaign Committee and the New York Regional Cabinet; a trustee and co-chair of the nominating and governance committee of the New York Hall of Science; and a member of the Columbia University Science Advisory Committee. He earned a B.A. in biology from Oberlin College, a B.S. and M.S. in chemical engineering from Washington University in St. Louis, and a Master of Business Administration with a concentration in finance from New York University.